ArticleCardiovascular diabetology2023

Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease.

J David Smeijer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.